Core Viewpoint - Company announced a placement and subscription agreement to raise approximately HKD 15.725 billion, enhancing its capital base for long-term development and drug pipeline funding [1][2] Group 1: Placement and Subscription Details - The seller, C-Bridge IV Investment Two Limited, will sell 22.561 million shares at a price of HKD 69.70 per share, representing about 6.87% of the total issued shares as of the announcement date [1] - The subscription shares will equal the number of shares sold, leading to an enlarged total issued share capital of approximately 6.43% post-completion [1] Group 2: Use of Proceeds - The net proceeds from the placement and subscription are expected to be around HKD 15.534 billion, which will be allocated as follows: 50% for global R&D of pipeline products, 40% for commercialization efforts including new product launches, and 10% for general administrative expenses [2]
云顶新耀(01952.HK)拟先旧后新配股总筹15.7亿港元 加速全球研发及商业化布局